Scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer's Disease

Advances in Pharmacology

Volumn 64, Issue , 2012, Pages 177-212

  Ma, Keran ^a   Thomason, Lynsie A M ^a   McLaurin, JoAnne ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alzheimers disease; Amyloid; Clinical trials; Mouse models; Scyllo inositol

Indexed keywords

1,4 DI O METHYL SCYLLO INOSITOL; BROMOCONDURITOL; CARRIER PROTEIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLURBIPROFEN; INOSITOL; MEMBRANE PROTEIN; MYOINOSITOL 2 DEHYDROGENASE; PLACEBO; PROTEIN PROTON MYO INOSITOL TRANSPORTER; PROTEIN SODIUM MYO INOSITOL TRANSPORTER 1; PROTEIN SODIUM MYO INOSITOL TRANSPORTER 2; SCYLLO INOSITOL; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ACETOBACTER; ALZHEIMER DISEASE; ARTICLE; BACILLUS SUBTILIS; BREAST CANCER; BURKHOLDERIA; CANCER PATIENT; CARDIOVASCULAR DISEASE; CYCLIZATION; DRUG COST; DRUG METABOLISM; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GLIOBLASTOMA; GOUT; HUMAN; HYDROLYSIS; HYDROPHOBICITY; HYPERTENSION; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; LONG TERM POTENTIATION; MASS FRAGMENTOGRAPHY; MAZE TEST; METABOLIC SYNDROME X; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; SINGLE DRUG DOSE; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; XENOPUS;

EID: 84864300783     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-394816-8.00006-4     Document Type: Chapter

References (121)

1. Anderson C., Wallis E.S.J. The catalytic hydrogenation of polyhydric phenols. I. The synthesis of meso-inositol, scyllitol and a new isomeric cyclitol. American Chemical Society 1948, 70:2931-2935.
2. Angyal S.J., Matheson N.K. Cyclitols. III. Some tosyl esters of inositols. Synthesis of a new inositol. Journal of American Chemical Society 1955, 77:4343-4346.
3. Angyal S.J., Odier L., Tate M.E. A simple synthesis of cis-inositol. Carbohydrate Research 1995, 266:143-146.
4. Aytan N., Carreras I., Choi J.-K., Kowall N.W., Jenkins B.G., Dedeoglu A. Effects of scyllo-inositol in a novel transgenic model of Alzheimer's disease 2011, http://www.sfn.org/am2011/index.aspx%3fpagename%3dfinal_program.
5. Balandrin M.F., Klocke J.A., Wurtele E.S., Bollinger W.H. Natural plant chemicals: Sources of industrial and medicinal materials. Science 1985, 228:1154-1160.
6. Bastianetto S., Krantic S., Quirion R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: Possible significance to Alzheimer's disease. Mini Reviews in Medicinal Chemistry 2008, 8:429-435.
7. + /myo-lnositol cotransporter gene (SLC5A3): Molecular cloning and localization to chromosome 21. Genomics 1995, 25:507-513.
8. + /myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea. Journal of Biological Chemistry 2003, 278:18297-18302.
9. Bissonnette P., Coady M.J., Lapoi J. Expression of the sodium-myo-inositol cotransporter SMIT2 at the apical membrane of Madin-Darby canine kidney cells. Journal of Physiology 2004, 558:759-768.
10. + -myo-inositol cotransporter SMIT2 stably transfected in the Madin-Darby canine kidney cell line. American Journal of Physiology. Cell Physiology 2008, 295:791-799.
11. Bouveault L. De l'isomérie optique dans les corps a' chaines fermées. Bulletin de la Societe Chimique de Paris 1894, 11:144-147.
12. Candy D.J. Occurrence and metabolism of scyllo-inositol in the locust. Biochemical Journal 1967, 103:666-671.
13. Cedarbaum J.M. United States Patent Application Publication: Methods of treatment of hyperuricemia and associated disease states. Elan Pharmaceuticals 2009, application number 12/560,113US 2010/0152305 A1. http://www.google.com/patents/.
14. Chishti M.A., Yang D., Janus C., Phinney A.L., Horne P., Pearson J., et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. Journal of Biological Chemistry 2001, 276:21562-21570.
15. Choi J.-K., Carreras I., Dedeoglu A., Jenkins B.G. Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimers disease mouse models. Neuropharmacology 2010, 59:353-357.
16. Chung S.K., Kwon Y.U. Practical synthesis of all inositol stereoisomers from myo-inositol. Bioorganic & Medicinal Chemistry Letters 1999, 9:2135-2140.
17. + /myo-inositol cotransporter. Journal of Biological Chemistry 2002, 277:35219-35224.
18. Cook G.J. Pitfalls in PET/CT interpretation. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2007, 51:235-243.
19. Cruz A. United States Patent Application Publication: Treatment of macular degeneration-related disorders 2009, Application number 12/576,957. http://www.google.com/patents/US20100093648.
20. DaSilva K.A., Brown M.E., Cousins J.E., Rappaport R.V., Aubert I., Westaway D., et al. scyllo-Inositol (ELND005) ameliorates amyloid pathology in an aggressive mouse model of Alzheimer's disease 2009, Key={081F7976-E4CD-4F3D-A0AF-E8387992A658}. http://www.abstractsonline.com/Plan/ViewAbstract.aspx%3F.
21. Devanand D.P., Mikhno A., Pelton G.H., Cuasay K., Pradhaban G., Dileep Kumar J.S., et al. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. Journal of Geriatric Psychiatry Neurology 2010, 23:185-198.
22. + /myo-inositol transporter HMIT. BMC Cell Biology 2009, 10:54.
23. Dihr A. Pentylenetetrazol (PTZ) kindling model of epilepsy. Currunt Protocol in Neuroscience 2012, 58:9.37.1-9.37.12.
24. Elan Corporation Press Release Elan Provides an Update on ELND005 (scyllo-inositol) 2011, November 29, 2011. http://newsroom.elan.com/phoenix.zhtml%3fc%3d88326%26p%3dirol-newsArticle%26ID%3d1634478%26highlight%3d.
25. Elmaleh D., Shoup T., Fu H., Johnson K., Selkoe D., Fischman A. Synthesis and evaluation of a series of scyllo-inositol/2-(fluoroethyl)-8-methyl-2,8-diazaspirol[4,5]decane-1,3-dione combined derivatives as potential amyloid-beta polymerization inhibitors and PET oligomer-Abeta probes. Journal of Nuclear Medicine 2010, 51:1497.
26. Feng Y., Wang X.P., Yang S.G., Wang Y.J., Zhang X., Du X.T., et al. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 2009, 30:986-995.
27. Fenili D., Brown M., Rappaport R., McLaurin J. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. Journal of Molecular Medicine (Berliner) 2007, 85:603-611.
28. Fenili D., Ma K., McLaurin J. scyllo-Inositol: A potential therapeutic for Alzheimer's disease. Emerging Drugs and Targets for Alzheimer's Disease 2010, 1:94-116). Royal Society of Chemistry, England. A. Martinez (Ed.).
29. Fenili D., Weng Y.-Q., Aubert I., Nitz M., McLaurin J. Sodium/myo-Inositol transporters: substrate transport requirments and regional brain expression in the TgCRND8 mouse model of amyloid pathology. PLoS One 2011, 6. e24032.
30. Ferrão-Gonzales A.D., Robbs B.K., Moreau V.H., Ferreira A., Juliano L., Valente A.P., et al. Controlling β-amyloid oligomerization by the use of naphthalene sulfonates. Journal of Biological Chemistry 2005, 280:34747-34754.
31. Fisher S.K., Novak J.E., Agranoff B.W. Inositol and higher inositol phosphates in neural tissues: Homeostasis, metabolism and functional significance. Journal of Neuroscience 2002, 82:736-754.
32. Fox N.C., Black R.S., Gilman S., et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 10:1563-1572.
33. Garzone P., Koller M., Pastrak A., Jhee S.S., Ereshefsky L., Moran S., et al. Oral amyloid anit-aggregation agent ELND005 is measurable in CSF and brain of healthy adult men. Alzheimer's and Dementia 2009, 5(Suppl):323.
34. Goodson J.A. Constituents of the leaves of. Helinus ovatus. Journal of Chemical Society, Transactions 1920, 117:140-144.
35. Hager K., Hazama A., Kwon H.M., Loo D.D., Handler J.S., Wright E.M. Kinetics and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus oocytes. Journal of Membrane Biology 1995, 143:103-113.
36. Hann R.M., Sando C.E. Scyllitol from flowering dogwood (Cornus florida). Journal of Biological Chemistry 1926, 68:399-402.
37. Hakvoort A., Haselbach M., Galla H. Active transport properties of porcine choroid plexus cells in culture. Brain Research 1998, 795:247-256.
38. Hawkes C.A., Deng L.H., Shaw J.E., Nitz M., McLaurin J. Small molecule beta-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. European Journal of Neuroscience 2010, 31:203-213.
39. Hawkes C.A., Deng L., Fenili D., Nitz M., McLaurin J. In vivo uptake of β-amyloid by non-plaque associated microglia. Current Alzheimer Research 2012, [BSP/CAR/E-Pub/00096].
40. Hipps P.P., Holland W.H., Sherman W.R. Interconversion of myo- and scyllo-inositol with simultaneous formation of neo-inositol by an NADP+ dependent epimerase from bovine brain. Biochemical and Biophysical Research Communications 1977, 77:340-346.
41. Holcomb L., Gordon M.N., McGowan E., Yu X., Benkovic S., Jantzen P., et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nature Medicine 1998, 4:97-100.
42. Holub B.J. Metabolism and function of myo-inositol and inositol phospholipids. Annual Review of Nutrition 1986, 6:563-597.
43. Inoue K., Shimada Y., Minami H., Morimura A., Miyai A., Yamauchi A., et al. Cellular localization of Na+/myo-inositol co-transporter mRNA in the rat brain. Neuroreport 1996, 7:1195-1198.
44. Isaacks R.E., Bender A.S., Kim C.Y., Shi Y.F., Norenberg M.D. Effect of osmolality and anion channel inhibitors on myo-inositol efflux in cultured astrocytes. Journal of Neuroscience Research 1999, 57:866-871.
45. Ishibashi K.-I., Tomiyama T., Nishitsuji K., Hara M., Mori H. Absence of synaptophysin near cortical neurons containing oligomer Aβ in Alzheimer's disease brain. Journal of Neuroscience Research 2006, 84:632-636.
46. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
47. Kage-Nakadai E., Uehara T., Mitani S. H+/myo-inositol transporter genes, hmit-1.1 and hmit-1.2, have roles in the osmoprotective response in Caenorhabditis elegans. Biochemical and Biophysical Research Communications 2011, 410:471-477.
48. Karran E., Mercken M., De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: An appraisal for the development of therapeutics. Nature Reviews Drug Discovery 2011, 10:698-712.
49. Kelly B.L., Vassar R., Ferreira A. Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. Journal of Biological Chemistry 2005, 280(36):31746-31753.
50. Klyubin I., Walsh D.M., Lemere C.A., Cullen W.K., Shankar G.M., Betts V., et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nature Medicine 2005, 11:556-561.
51. Kokkoni N., Stott K., Amijee H., Mason J.M., Doig A.J. N-Methylated peptide inhibitors of beta-amyloid aggregation and toxicity. Optimization of the inhibitor structure. Biochemistry 2006, 45:9906-9918.
52. Kokubo H., Kayed R., Glabe C.G., Saido T.C., Iwata N., Helms J.B., et al. Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain. Brain Research 2005, 1045:224-228.
53. Kowarski C., Sarel S.J. Total stereoselective synthesis of myo-, allo-, neo-, and epi-inositols. Journal of Organic Chemistry 1973, 38:117-119.
54. Kwon H.M., Yamauchi A., Uchida S., Preston A.S., Garcia-Perez A., Burg M.B., et al. Cloning of the cDNa for a Na+/myo-inositol cotransporter: A hypertonicity stress protein. Journal of Biological Chemistry 1992, 267:6297-6301.
55. Lacor P.N., Buniel M.C., Chang L., Fernandez S.J., Gong Y., Viola K.L., et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. Journal of Neuroscience 2004, 24:10191-10200.
56. Larner J., Jackson W.T., Graves D.J., Stamer J.R. Inositol dehydrogenase from aerobacter aerogenes. Archives of Biochemistry and Biophysics 1956, 60:352-363.
57. Liang E., Cedarbaum J., Abushakra S., Green M., Yan L., Wagg J. Population pharmacokinetic analysis of plasma, cerebrospinal fluid and brain ELND005 in patients with mild to moderate Alzheimer's disease. Alzheimer's and Dementia 2009, 5(Suppl):465.
58. Lin X., Ma L., Fitzgerald R.L., Ostlund R.E. Human sodium/inositol cotransporter 2 (SMIT2) transports inositols but not glucose in L6 cells. Archives of Biochemistry and Biophysics 2009, 481:197-201.
59. Loveday D., Heacock A.M., Fisher S.K. Activation of muscarinic cholinergic receptors enhances the volume-sensitive efflux of myo-inositol from SH-SY5Y neuroblastoma cells. Journal of Neurochemistry 2003, 87:476-486.
60. Mandel M., Hudlicky T.J. General synthesis of inositols by hydrolysis of conduritol epoxides obtained biocatalytically from halogenobenzenes: (+)-D-chiro-inositol, allo-inositol, muco-inositol and neo-inositol. Journal of the Chemical Society. Perkin Transaction 1993, 1:741-743.
61. Matskevitch J., Wagner C.A., Risler T., Kwon H.M., Handler J.S., Waldegger S., et al. Effect of extracellular pH on the myo-inositol transporter SMIT expressed in Xenopus oocytes. Pflugers Archive 1998, 436:854-857.
62. McLarty K., Moran M.D., Scollard D.A., Chan C., Sabha N., Mukherjee J., et al. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nuclear Medicine Biology 2011, 38:953-959.
63. McLaurin J., Chakrabartty A. Membrane disruption by Alzheimer β-amyloid peptides mediated through specific binding to either phospholipids or gangliosides. Journal of Biological Chemistry 1996, 271:26482-26489.
64. McLaurin J., Chakrabartty A. Characterization of the interactions of Alzheimer β-amyloid peptides with phospholipid membranes. European Journal of Biochemistry 1997, 245:355-363.
65. McLaurin J., Franklin T., Chakrabartty A., Fraser P.E. Phosphatidylinositol and inositol involvement in Alzheimer amyloid-β fibril growth and arrest. Journal of Molecular Biology 1998, 278:183-194.
66. McLaurin J., Golomb R., Jurewiczi A., Anteli J.P., Fraser P.E. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid β peptide and inhibit Aβ-induced toxicity. Journal of Biological Chemistry 2000, 275:18495-18502.
67. McLaurin J., Kierstead M.E., Brown M.E., Hawkes C.A., Lambermon M.H., Phinney A.L., et al. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nature Medicine 2006, 12:801-808.
68. McPhie R.P., Campana S.E. Reproductive characteristics and population decline of four species of skate (Rajidae) off the eastern coast of Canada. Journal of Fish Biology 2009, 75:233-246.
69. McVeigh K.E., Mallee J.J., Lucente A., Barnoski B.L., Wu S., Berry G.T. Murine chromosome 16 telomeric region, homologous with human chromosome 21q22, contains the osmoregulatory Na(+)/myo-inositol cotransporter (SLC5A3) gene. Cytogenetics and Cell Genetics 2000, 88:153-158.
70. Michell R.H. Inositol derivatives: Evolution and functions. Nature Reviews Molecular Cell Biology 2008, 9:151-161.
71. Müller H. Cocositol (cocosite), a constituent of the leaves of "Cocos nucifera" and "cocos plumosa" Journal of the Chemical Society Transactions 1907, 91:1767-1780.
72. Müller H. Inositol and some of its isomerides. Journal of the Chemical Society Transaction 1912, 101:2383-2410.
73. Müller K., Faeh C., Diederich F. Fluorine in pharmaceuticals: looking beyond intuition. Science 2007, 317:1881-1886.
74. Novak J.E., Agranoff B.W., Fisher S.K. Regulation of myo-inositol homeostasis in differentiated human NT2-N neurons. Neurochemical Research 2000, 25(5):561-566.
75. Nozadze M., Mikautadze E., Lepsveridze E., Mikeladze E., Kuchiashvili N., Kiguradze T., et al. Anticonvulsant activities of myo-inositol and scyllo-inositol on pentylenetetrazol induced seizures. Seizure 2011, 20:173-176.
76. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: Potential factors in amyloid plaque formation. Journal of Neuroscience 2006, 26:10129-10140.
77. Oddo S., Caccamo A., Kitazawa M., Tseng B.P., LaFerla F.M. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiology of Aging 2003, 24:1063-1070.
78. Ostlund R.E., Seemayer R., Gupta S., Kimmel R., Ostlund E.L., Sherman W.R. A stereospecific myo-inositol/D-chiro-inositol transporter in HepG2 liver cells. Identification with D-chiro-[3-3H]inositol. Journal of Biological Chemistry 1996, 271:10073-10078.
79. Pal A., Mukhapadhyay U., Volgin A., Shavrin A., Tong W., Gelovani J., Alauddin M. Radiosynthesis of 2-[18F]fluoro-2-deoxy-scyllo-inositol for PET imaging of phosphadtidylinositol pool in PI3 kinase activity. Journal of Nuclear Medicine 2009, 50:261.
80. Park S., Pegan S.D., Mesecar A.D., Jungbauer L.M., LaDu M.J., Liebman S.W. Development and validation of a yeast high-throughput screen for inhibitors of Aβ42 oligomerization. Disease Models & Mechanisms 2011, 4:822-831.
81. Podeschwa M., Plettenburg O., vom Brocke J., Block O., Adelt S., Altenbach H.-J. Stereoselective synthesis of myo-, neo-, L-chiro, D-chiro, allo-, scyllo-, and epi-inositol systems via conduritols prepared from p-benzoquinon. European Journal of Organic Chemistry 2003, 2003:1958-1972.
82. Posternak T. Les Cyclitols. Hermann 1965, 97.
83. Praveen T., Shashidhar M.S. Convenient synthesis of 4,6-di-O-benzyl-myo-inositol and myo-inositol 1,3,5-orthoesters. Carbohydrate Research 2001, 330:409-411.
84. Prince M., Bryce R., Ferri C. Alzheimer's Disease International World Alzheimer Report 2011 The benefits of early diagnosis and intervention 2011, January 25, 2012. http://www.alz.co.uk/research/WorldAlzheimerReport2011ExecutiveSummary.pdf.
85. Quinn K., Brigham B., Soriano F., Connop B., Sauer J.M. ELD005 (scyllo-inositol), the β-amyloid anti-aggregation therapeutic, demonstrates robust brain uptake in rats following oral administration. Alzheimer's and Dementia 2009, 5(Suppl):437.
86. Ramaley R., Fujita Y., Freese E. Purification and properties of Bacillus subtilis inositol dehydrogenase. Journal of Biological Chemistry 1979, 254:7684-7690.
87. Reddy R.E., Chemburkar S.R., Spaulding D.R., Pan Y., Cao L., Restituyo J.A., et al. (United States patent application: Process for the preparation of scyllo-inositol). United States patent application number 2011, 20110201060. http://patents.com/us-20110201060.html.
88. Rinne J.O., Brooks D.J., Rossor M.N., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending dose study. Lancet Neurology 2010, 9:363-372.
89. Roll P., Massacrier A., Pereira S., Robaglia-Schlupp A., Cau P., Szepetowski P. New human sodium/glucose cotransporter gene (KST1): Identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families. Gene 2002, 285:141-148.
90. Salloway S., Sperling R., Keren R., Porsteinsson A.P., van Dyck C.H., Tariot P.N., et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology 2011, 77:1253-1262.
91. Sanz M.L., Villamiel M., Martinez-Castro I. Inositols and carbohydrates in different fresh fruit juices. Food Chemistry 2004, 87:325-328.
92. Sarmah M.P., Shashidhar M.S. Sulfonate protecting groups. Improved synthesis of scyllo-inositol and its orthoformate from myo-inositol. Carbohydrate Research 2003, 338:999-1001.
93. Seaquist E.R., Gruetter R. Identification of a high concentration of scyllo-inositol in the brain of a healthy human subject using 1H- and 13C-NMR. Magnetic Resonance in Medicine 1998, 39:313-316.
94. Shaldubina A., Buccafusca R., Johanson R.A., Agam G., Belmaker R.H., Berry G.T., Bersuds Y. Behavioural phenotyping of sodium-myo-inositol cotransporter heterozygous knockout mice with reduced brain inositol. Genes Brain Behavior 2007, 6(3):253-259.
95. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. Journal of Neuroscience 2007, 27(11):2866-2875.
96. Shaw J.E., Chio J., Dasgupta S., Lai A.Y., Mo G.C.H., F.Pang F., et al. Assembly in the presence of scyllo-inositol derivatives: Identification of an oxime linkage as important for the development of assembly inhibitors. ACS Chemical Neuroscience 2011, 1-42. http://dx.doi.org/10.1021/cn2000926.
97. Sherman W.R., Stewart M.A., Kurien M.M., Goodwin S.L. The measurement of myo-inositol, myo-inosose-2 and scyllo-inositol in mammalian tissues. Biochemica et Biophysica Acta 1968, 158:197-205.
98. Sherman W.R., Simpson P.C., Goodwin S.L. scyllo-Inositol and myo-inositol levels in tissues of the skate Raja erinacea. Comparative Biochemistry and Physiology B 1978, 59. 201-201.
99. Shim Y.S., Morris J.C. Biomarkers predicting Alzheimer's disease in cognitively normal aging. Journal of Clinical Neurology 2011, 7:60-68.
100. Shoup T., Elmaleh D., Carter E., Winter D., Tolman C., Fischman A. Synthesis and biodistribution of F-18 labeled scyllo-inositol derivatives as potential probes for decting amyloid beta oligomers. Journal of Nuclear Medicine 2009, 50:1935.
101. Soria A.C., Sanz M.L., Villamiel M. Determination of minor carbohydrates in carrot (Daucus carota L.) by GC-MS. Food Chemistry 2009, 114:758-762.
102. Spector R. The specificity and sulfhydryl sensitivity of the inositol transport system of the central nervous system. Journal of Neurochemistry 1976, 27:229-236.
103. Sun Y., Zhang G., Hawkes C.A., Shaw J.E., McLaurin J., Nitz M. Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation. Bioorganic & Medicinal Chemistry 2008, 16:7177-7184.
104. Tagliaferri F., Wang S.-N., Berlin W.K., Outten R.A., Shen T.Y. Glycosyl-inositol derivatives. I. Synthesis of 1-substituted chiro-inositol derivatives. Tetrahedron Letters 1990, 31:1105-1108.
105. Takahashi H., Kittaka H., Ikegami S. Novel synthesis of enantiomerically pure natural inositols and their diastereoisomers. Journal of Organic Chemistry 2001, 66:2705-2716.
106. Townsend M., Cleary J.P., Mehta T., Hofmeister J., Lesne S., O'Hare E., et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Annals of Neurology 2006, 60:668-676.
107. + -myo-inositol symporter expressed predominantly in the brain. EMBO Journal 2001, 20:4467-4477.
108. + /myo-inositol symporter at synapses and growth cones. EMBO Journal 2004, 23:531-540.
109. Vasdev N., Chio J., van Oosten E.M., Nitz M., McLaurin J., Vines D.C., et al. Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol. Chemical Communications (Cambridge) 2009, 37:5527-5529.
110. Vekrellis K., Xilouri M., Emmanouilidou E., Stefanis L. Inducible over-expression of wild type α-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. Journal of Neurochemistry 2009, 109:1348-1362.
111. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416:535-539.
112. Watanabe Y., Mitani M., Ozaki S. Synthesis of optically active inositol derivatives starting from D-glucurono-6,3-lactone. Chemistry Letters 1987, 123-126.
113. Watanabe T., Shiino A., Akiguchi I. Absolute quantification in proton magnetic resonance spectroscopy is useful to differentiate amnesic mild cognitive impairment from Alzheimer's disease and healthy aging. Dementia and Geriatric Cognitive Disorders 2010, 30:71-77.
114. Williams L.J., Cicia A.M., Pellegrin G.B., Smith K.M., Sulikowski J.A. The reproductive cycle of the roundel skate Raja texana. Journal of Fish Biology 2011, 79:298-305.
115. Yamaguchi M., Kita Y., Mori T., Kanbe K., Tomoda A., Takahashi A., et al. United States Patent: Method for producing scyllo-inositol. Hokko Chemicals 2004, Patent number US7745671. http://www.freepatentsonline.com/7745671.html.
116. Yamaoka M., Osawa S., Morinaga T., Takenaka S., Yoshida K. A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease. Microbial Cell Factories 2011, 10:69.
117. Yap I.K., Brown I.J., Chan Q., Wijeyesekera A., Garcia-Perez I., Bictash M., et al. Metabolome-wide association study identifies multiple biomarkers that discriminate north and south Chinese populations at differing risks of cardiovascular disease: INTERMAP study. Journal of Proteome Research 2010, 9(12):6647-6654.
118. Yoshida K., Yamaguchi M., Morinaga T., Ikeuchi M., Kinehara M., Ashida H. Genetic modification of Bacillus subtilis for production of D-chiro-inositol, an investigational drug candidate for treatment of type 2 diabetes and polycystic ovary syndrome. Applied and Environmental Microbiology 2006, 72:1310-1315.
119. Yoshida K., Yamaguchi M., Morinaga T., Kinehara M., Ikeuchi M., Ashida H., et al. myo-Inositol catabolism in Bacillus subtilis. Journal Biological Chemistry 2008, 283:10415-10424.
120. Zhao F., Keating A.F. Functional properties and genomics of glucose transporters. Current Genomics 2007, 8:113-128.
121. Zhao W., Toolan D., Hepler R.W., Wolfe A.L., Yu Y., Price E., et al. High throughput monitoring of amyloid-β42 assembly into soluble oligomers achieved by sensitve confomation state-dependent immunoassays. Journal of Alzheimer's Disease 2011, 25:655-669.